Zürich University Hospital starts using Stockholm3
October 31, 2022
Zürich University Hospital has started using Stockholm3 for prostate cancer testing. This is the first clinic in Switzerland that uses Stockholm3.
Stockholm3 will be used for men aged 45 to 75 and offered to men in Switzerland. The blood tests will be taken at the Zürich University Hospital and the test analysis will be performed by A3P at its lab facility in Uppsala, Sweden. Men that have an elevated risk for prostate cancer will be offered an MRI examination and state-of-the-art prostate biopsy for further medical clarification. The University Hospital Zürich provides a great bandwidth of interdisciplinary treatment options ranging from focal therapy to surgery and medical and radiotherapy.
“Early detection of prostate cancer is of utmost importance for therapy success and quality of life of the patient. Thus, prostate cancer screening has to be elevated to the next level of innovation and precision. We are therefore very happy that we can now offer Stockholm3 to our patients to improve treatment and well-being,” says Prof. Dr. Daniel Eberli, clinic director for the urology clinic of Zürich University Hospital.
“We see a growing interest for Stockholm3 from clinicians all over the world and are very happy that the test is now available for Swiss men for the first time,” says David Rosén, CEO of A3P Biomedical.
About A3P Biomedical
A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com
About Stockholm3
Stockholm3 is a blood-based test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.
Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care, as a reflex test to PSA at values 1.5-20 ng/ml. Benefits include the ability to reduce unnecessary MRIs, benign and Grade Group 1 prostate biopsies for men with elevated PSA, while simultaneously improving detection of clinically significant cancers in men with low or normal PSA values. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 40-90% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 40-50% compared to PSA.
Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about our clinical studies please visit www.a3p.com.
About prostate cancer
Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.
Press contact:
Cecilia Edström
cecilia.edstrom@a3p.com
+46 72 226 2328